Cempra, Inc. and Macrolide Pharmaceuticals, Inc. have entered an agreement under which Macrolide will apply its synthesis technology to provide Cempra with a fully synthetic process for its late-stage investigational macrolide antibiotic, solithromycin for the treatment of community acquired bacterial pneumonia.   Solithromycin is currently manufactured using clarithromycin, a fermentation–derived antibiotic, as the starting material. Macrolide will partner with Cempra to develop a fully synth...